Latest Sales Growth News

Korvest has reported record full-year earnings for FY25, driven by a surge in major project revenue and strong cash flow, while approving a significant expansion of its Kilburn manufacturing facility.

Nuchev Limited reports a record-breaking Q4 FY25 with revenues soaring 167% year-on-year, driven by strong growth across multiple markets and a strategic agency agreement in Australia.

Universal Biosensors reports a $1.59 million improvement in operating cash outflows for Q2 2025, maintaining $2.55 million in cash as it advances commercialization across blood, wine, and water testing markets.

Australian Strategic Materials (ASM) reports significant progress in Q2 2025, including its first commercial heavy rare earth metals sale and a transformative low-cost production pathway at its Dubbo Project.

Firebrick Pharma has published positive Phase 3 clinical trial results for its Nasodine nasal spray, showing efficacy against the common cold, while reporting encouraging sales growth in Singapore and the US. However, a recent capital raise fell well short of targets, casting uncertainty over its expansion plans.

Generation Development Group reports a transformative FY25 with record Investment Bond sales and successful integration of Evidentia and Lonsec managed accounts, setting the stage for strong growth in FY26.

AnteoTech has signed a binding Term Sheet with US-based Black Diamond Structures to jointly develop and commercialise an advanced battery additive combining their proprietary technologies, targeting improved lithium-ion battery anodes with higher silicon content.

Meridian Energy’s June 2025 report reveals hydro storage levels exceeding historical averages and a notable rise in retail electricity sales, despite lower generation prices. The company also signals the end of its smelter demand response agreement.

Biome Australia Limited has reported a 69% increase in international sales revenue for FY25, reaching $1.5 million, driven by new strategic distribution agreements across Ireland, New Zealand, and Canada.

MyEco Group Ltd reported an 8.6% rise in FY25 sales driven by strong growth in its global MyEco® product line and new UK retail partnerships, while navigating challenges in resin markets and US tariffs.

Orthocell has achieved a significant milestone by recording its first US sales revenue for Remplir™, its flagship nerve repair product, shortly after FDA clearance and initial surgical use.

Biome Australia Limited has confirmed its record FY25 sales revenue of approximately $18.4 million, marking a 41% increase year-on-year, while affirming full compliance with ASX continuous disclosure rules.